Proceedings of a National Cancer Institute workshop: PET in oncology - A clinical research agenda

Richard L. Wahl; Randall A. Hawkins; Steven M. Larson; William R. Hendee; R. Edward Coleman; Robert W. Holden; Mathis P. Frick; Constantine Gatsonis; G. Stephen Brown; Faina Shtern

doi:10.1148/radiology.193.3.7972793

Proceedings of a National Cancer Institute workshop: PET in oncology - A clinical research agenda

Richard L. Wahl, Randall A. Hawkins, Steven M. Larson, William R. Hendee, R. Edward Coleman, Robert W. Holden, Mathis P. Frick, Constantine Gatsonis, G. Stephen Brown, Faina Shtern

Research output: Contribution to journal › Editorial

35 Scopus citations

Abstract

On November 28, 1992, the National Cancer Institute sponsored a workshop to discuss the current state of positron emission tomography (PET) applications in clinical oncology and to identify areas of consensus regarding a targeted research agenda in this growing field. Workshop members concluded that PET with the use of the glucose analog 18-F-fluoro-2-deoxy-D- glucose (FDG) has demonstrated substantial clinical potential as a method to (a) depict and characterize masses, (b) depict regional metastatic disease involving lymph nodes, (c) depict systemic metastases of cancer, and (d) help assess the response of cancers to a variety of therapies. More broad-based research directed at advancing our ability to apply the PET method to cancer diagnosis and treatment monitoring is needed. There was also a consensus that rigorous prospective trials of the PET method should be performed with current technology, transverse attenuation-corrected PET scans to determine the accuracy of PET in the characterization and regional staging of primary lung and breast cancers. Rational application of the PET method to cancer management will be accomplished better after the results of these research studies become available.

Original language	English
Pages (from-to)	604-606
Number of pages	3
Journal	Radiology
Volume	193
Issue number	3
DOIs	https://doi.org/10.1148/radiology.193.3.7972793
State	Published - Dec 1994

Keywords

Editorials
Emission CT (ECT)
Neoplasms, emission CT (ECT)

Access to Document

10.1148/radiology.193.3.7972793

Cite this

@article{eac56404f72d49dfa5f1e714ff733533,

title = "Proceedings of a National Cancer Institute workshop: PET in oncology - A clinical research agenda",

abstract = "On November 28, 1992, the National Cancer Institute sponsored a workshop to discuss the current state of positron emission tomography (PET) applications in clinical oncology and to identify areas of consensus regarding a targeted research agenda in this growing field. Workshop members concluded that PET with the use of the glucose analog 18-F-fluoro-2-deoxy-D- glucose (FDG) has demonstrated substantial clinical potential as a method to (a) depict and characterize masses, (b) depict regional metastatic disease involving lymph nodes, (c) depict systemic metastases of cancer, and (d) help assess the response of cancers to a variety of therapies. More broad-based research directed at advancing our ability to apply the PET method to cancer diagnosis and treatment monitoring is needed. There was also a consensus that rigorous prospective trials of the PET method should be performed with current technology, transverse attenuation-corrected PET scans to determine the accuracy of PET in the characterization and regional staging of primary lung and breast cancers. Rational application of the PET method to cancer management will be accomplished better after the results of these research studies become available.",

keywords = "Editorials, Emission CT (ECT), Neoplasms, emission CT (ECT)",

author = "Wahl, {Richard L.} and Hawkins, {Randall A.} and Larson, {Steven M.} and Hendee, {William R.} and Coleman, {R. Edward} and Holden, {Robert W.} and Frick, {Mathis P.} and Constantine Gatsonis and Brown, {G. Stephen} and Faina Shtern",

year = "1994",

month = dec,

doi = "10.1148/radiology.193.3.7972793",

language = "English",

volume = "193",

pages = "604--606",

journal = "Radiology",

issn = "0033-8419",

number = "3",

}

TY - JOUR

T1 - Proceedings of a National Cancer Institute workshop

T2 - PET in oncology - A clinical research agenda

AU - Wahl, Richard L.

AU - Hawkins, Randall A.

AU - Larson, Steven M.

AU - Hendee, William R.

AU - Coleman, R. Edward

AU - Holden, Robert W.

AU - Frick, Mathis P.

AU - Gatsonis, Constantine

AU - Brown, G. Stephen

AU - Shtern, Faina

PY - 1994/12

Y1 - 1994/12

N2 - On November 28, 1992, the National Cancer Institute sponsored a workshop to discuss the current state of positron emission tomography (PET) applications in clinical oncology and to identify areas of consensus regarding a targeted research agenda in this growing field. Workshop members concluded that PET with the use of the glucose analog 18-F-fluoro-2-deoxy-D- glucose (FDG) has demonstrated substantial clinical potential as a method to (a) depict and characterize masses, (b) depict regional metastatic disease involving lymph nodes, (c) depict systemic metastases of cancer, and (d) help assess the response of cancers to a variety of therapies. More broad-based research directed at advancing our ability to apply the PET method to cancer diagnosis and treatment monitoring is needed. There was also a consensus that rigorous prospective trials of the PET method should be performed with current technology, transverse attenuation-corrected PET scans to determine the accuracy of PET in the characterization and regional staging of primary lung and breast cancers. Rational application of the PET method to cancer management will be accomplished better after the results of these research studies become available.

AB - On November 28, 1992, the National Cancer Institute sponsored a workshop to discuss the current state of positron emission tomography (PET) applications in clinical oncology and to identify areas of consensus regarding a targeted research agenda in this growing field. Workshop members concluded that PET with the use of the glucose analog 18-F-fluoro-2-deoxy-D- glucose (FDG) has demonstrated substantial clinical potential as a method to (a) depict and characterize masses, (b) depict regional metastatic disease involving lymph nodes, (c) depict systemic metastases of cancer, and (d) help assess the response of cancers to a variety of therapies. More broad-based research directed at advancing our ability to apply the PET method to cancer diagnosis and treatment monitoring is needed. There was also a consensus that rigorous prospective trials of the PET method should be performed with current technology, transverse attenuation-corrected PET scans to determine the accuracy of PET in the characterization and regional staging of primary lung and breast cancers. Rational application of the PET method to cancer management will be accomplished better after the results of these research studies become available.

KW - Editorials

KW - Emission CT (ECT)

KW - Neoplasms, emission CT (ECT)

UR - http://www.scopus.com/inward/record.url?scp=0028046171&partnerID=8YFLogxK

U2 - 10.1148/radiology.193.3.7972793

DO - 10.1148/radiology.193.3.7972793

M3 - Editorial

C2 - 7972793

AN - SCOPUS:0028046171

SN - 0033-8419

VL - 193

SP - 604

EP - 606

JO - Radiology

JF - Radiology

IS - 3

ER -

Proceedings of a National Cancer Institute workshop: PET in oncology - A clinical research agenda

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this